Indeed, the SoC for treatment of naïve patients with NSCLC HER2 alterations (including also HER2 MUT) is still chemotherapy, associated with ICI producing non-lasting responses (up to 60% with a mPFS around 6 months) [26,27,28]. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.